BMS, Van­tAI team up; CRISPR Ther­a­peu­tics to raise $280M; Ono Phar­ma's deal with Shat­tuck Labs

Last year
News Briefing

Eye­Bio tar­gets reg­is­tra­tional tri­al af­ter ear­ly suc­cess of Wnt ag­o­nist in reti­nal dis­eases

Last year
R&D

BioAge rais­es $170M as obe­si­ty spot­light shifts to oral op­tions, mus­cle pre­servers

Last year
Financing
Startups

Has Os­car fi­nal­ly fig­ured out its health in­sur­ance busi­ness?

Last year
Health Tech

Up­dat­ed: Ex­sci­en­tia CEO brought down by al­le­ga­tions of in­ap­pro­pri­ate em­ploy­ee re­la­tion­ships, in blow to AI pi­o­neer

Last year
People

G1 Ther­a­peu­tic­s' stock sinks near­ly 40% on PhI­II read­out de­lay

Last year
R&D

Seat­tle biotech found­ed by for­mer Seagen lead­ers nabs $112M for three clin­i­cal-stage AD­Cs

Last year
Financing
Startups

Ot­su­ka’s fixed-dose com­bo dis­ap­points in PhI­II tri­al for Alzheimer’s ag­i­ta­tion

Last year
R&D

Judge toss­es PhRMA's suit over drug price ne­go­ti­a­tions in a win for the Biden ad­min­is­tra­tion

Last year
Pharma
Law

Roche walks away from Re­pare sol­id tu­mor deal just weeks af­ter $40M mile­stone pay­out

Last year
Deals
R&D

KalVista re­ports PhI­II suc­cess of on-de­mand, oral hered­i­tary an­gioede­ma drug as it seeks to chal­lenge in­jecta­bles

Last year
R&D

Stake­hold­ers brace for bumps in rare pe­di­atric dis­ease PRV reau­tho­riza­tion

Last year
Pharma
FDA+

House Re­pub­li­cans take is­sue with DO­J's han­dling of Mod­er­na's Covid vac­cine patents

Last year
Coronavirus

Neu­rol­o­gists val­ue speed and ef­fi­ca­cy over safe­ty for ALS pipeline drugs, study finds

Last year
Pharma
Marketing

Gilead­'s newest ac­qui­si­tion: a liv­er dis­ease drug with $1B in peak sales po­ten­tial

Last year
Deals

FTC re­view pe­ri­ods end for Ab­b­Vie-Im­muno­Gen $10.1B deal and $4B BMS-Rayze­Bio buy­out

Last year
Deals
Pharma

Co­me­di­ans dri­ve Vi­iV’s new rideshar­ing se­ries about HIV pre­ven­tion

Last year
Marketing

Take­da wins long-await­ed US ap­proval for first oral drug for eosinophilic esophagi­tis

Last year
Pharma
FDA+

FDA ad­dress­es ex­pand­ed use of da­ta mon­i­tor­ing com­mit­tees in draft guid­ance

Last year
Pharma
FDA+

Lari­mar Ther­a­peu­tics shares key bio­mark­er da­ta, aims for ac­cel­er­at­ed ap­proval for Friedre­ich’s atax­ia drug

Last year
R&D

Im­muno­van­t's plans for au­toim­mune as­set; Wall Street wor­ries about Mod­er­na’s RSV can­di­date 

Last year
News Briefing

In­fec­tious dis­ease biotech halts late-stage tri­al due to sub­par ef­fi­ca­cy, shares plum­met 70%

Last year
R&D

A sweep­ing form of search-and-re­place edit­ing has come for mR­NA

Last year
R&D
In Focus

Gilead to snap up liv­er dis­ease biotech CymaBay for $4.3B

Last year
Deals
Pharma
First page Previous page 201202203204205206207 Next page Last page
A service from the Financial Times